Prijeđi na sadržaj

Pegaptanib

Izvor: Wikipedija
Pegaptanib
(IUPAC) ime
RNK, ((2'-deoksi-2'-fluoro)C-Gm-Gm-A-A-(2'-deoksi-2'-fluoro)U-(2'-deoksi-2'-fluoro)C-Am-Gm-(2'-deoksi-2'-fluoro)U-Gm-Am-Am-(2'-deoksi-2'-fluoro)U-Gm-(2'-deoksi-2'-fluoro)C-(2'-deoksi-2'-fluoro)U-(2'-deoksi-2'fluoro)U-Am-(2'-deoksi-2'-fluoro)U-Am-(2'-deoksi-2'-fluoro)C-Am-(2'-deoksi-2'-fluoro)U-(2'deoksi-2'-fluoro)C-(2'-deoksi-2'-fluoro)C-Gm-(3'→3')-dT), 5'-estar sa α,α'-[4,12-diokso-6[[[5-(fosfoonoksi)pentil]amino]karbonil]-3,13-dioksa-5,11-diaza-1,15-pentadekanediil]bis[ω-metoksipoli(oksi-1,2-etanediil)], natrijum so[1]
Klinički podaci
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 222716-86-1
ATC kod S01LA03
PubChem[2][3] 24847876
DrugBank DB04895
ChEMBL[4] CHEMBL1201704 DaY
Hemijski podaci
Formula C294H342F13N107Na28O188P28[C2H4O]2n (n≈900)
Mol. masa ~50 Da
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Poluvreme eliminacije 10 dana
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Intravitrealno

Pegaptanib natrijum injekcija (prodajno ime Macugen) je inhibitor angiogeneze, koji se koristi za lečenje neovaskularne (vlažne) starosne makularne degeneracije (AMD).[5][6][7][8][9][10]

Reference

[uredi | uredi kod]
  1. Drug Information: Pegaptanib Sodium Injection Arhivirano 2013-12-14 na Wayback Machine-u
  2. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  3. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. „Macugen (pegaptanib)”. European Medicines Agency: 1–3. 2010. Arhivirano iz originala na datum 2013-12-13. Pristupljeno 2013-12-08. 
  6. Vinores SA: Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-8. PMID 17717967
  7. Wylegala E, Teper SJ: [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment] Klin Oczna. 2007;109(1-3):97-100. PMID 17687925
  8. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J: Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2007 Aug 10;. PMID 17693999
  9. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.  edit
  10. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.  edit

Literatura

[uredi | uredi kod]

Spoljašnje veze

[uredi | uredi kod]